InvestorsHub Logo
Followers 72
Posts 6197
Boards Moderated 0
Alias Born 05/01/2011

Re: None

Tuesday, 02/12/2019 11:16:16 AM

Tuesday, February 12, 2019 11:16:16 AM

Post# of 424150
Don't underestimate the importance/signalling in that obesity patent.

If EPA helps substantially with weight control, that's arguably bigger than the CV benefit.

There are way more fat people than any category you can come up with.

It seems dumb, but if EPA controls weight, that'll sell more Vascepa than any CV benefit would.

Think Viagra -- that was supposed to be for lowering blood pressure.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News